What is RxSight, Inc.'s R&D?

RxSight, Inc. (RXST) reported R&D of $9.47M in Q1 2026.

How has RxSight, Inc.'s R&D changed year-over-year?

RxSight, Inc.'s R&D decreased by 8.6% year-over-year, from $10.37M to $9.47M.

What is the long-term trend for RxSight, Inc.'s R&D?

Over 4 years (2021 to 2025), RxSight, Inc.'s R&D has grown at a 12.0% compound annual growth rate (CAGR), from $24.5M to $38.55M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

RxSight, Inc. RXST R&D

R&D at other companies

LENSAR, Inc.LNSR

$1.39M-9.7%

Schering-PloughSGP

$8.54M+41.1%

Ocular TherapeutixOCUL

$66.21M+54.5%

Precision Optics CorporationPOCI

$267.32K+26.5%

Bausch + LombBLCO

$101M+17.4%

GlaukosGKOS

$44.15M+36.4%

Other financials

Income statement

See full

Revenue$30.9M-18.5%

Gross profit$23.5M-17.1%

Operating income-$17.8M-67.0%

Net income-$15.9M-93.9%

EPS (diluted)-$0.38-90.0%

Balance sheet

See full

Cash & equivalents$17.6M-37.2%

Total debt$10.8M-10.1%

Total equity$267.3M-4.3%

Total assets$304.0M-2.9%

Cash flow

See full

Operating cash flow-$10.9M-23.3%

CapEx$759.0K+32.0%

Free cash flow-$11.7M-23.8%

Valuation

See full

Market cap$232.23M-56.8%

Enterprise value$225.49M-55.7%

P/S1.8×-1.8×

Profitability

See full

Gross margin77%+5.1pp

Operating margin-43.4%+128pp

Net margin-36.6%-867pp

FCF margin-16.9%+4.9pp

Returns & leverage

See full

Return on equity-17.1%+12.6pp

Debt / equity0×0.0×

Current ratio10.2×-2.5×

Where this comes from

Reported directly by RxSight, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: RxSight, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about RxSight, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is RxSight, Inc.'s R&D?: RxSight, Inc. (RXST) reported R&D of $9.47M in Q1 2026.
How has RxSight, Inc.'s R&D changed year-over-year?: RxSight, Inc.'s R&D decreased by 8.6% year-over-year, from $10.37M to $9.47M.
What is the long-term trend for RxSight, Inc.'s R&D?: Over 4 years (2021 to 2025), RxSight, Inc.'s R&D has grown at a 12.0% compound annual growth rate (CAGR), from $24.5M to $38.55M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.